Treatment of vHCC with momelotinib reduced the expression of cancer stemness markers, such as CD133, KLF4, and SOX2, and decreased ALDH1 activity (Figure 4), suppressing tumorsphere and colony formation of HCC cells. Here, SOX2 is linked to cancer.